GlassScriptPhysician profile
Camille D Nelson
NPI 1548284516
$4,437.93
in general payments reported to CMS, 2019-2025
27 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $560 · 2021: $1,370 · 2022: $443 · 2023: $462 · 2024: $416 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $974.68 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $702.60 | 2019-2025 | |
| Pfizer INC. | $535.48 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $293.91 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $268.21 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $174.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $149.87 | 2022-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $147.50 | 2020-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.15 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.87 | 2021-2025 | Jardiance |
| Edwards Lifesciences Corporation | $123.61 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $106.24 | 2021-2022 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Amgen INC. | $87.50 | 2019-2021 | |
| Amarin Pharma, INC. | $77.26 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $61.92 | 2019-2021 | |
| Abbvie INC. | $59.52 | 2021 | |
| Abiomed | $53.44 | 2021-2025 | |
| Boston Scientific Corporation | $50.23 | 2024 | Varithena Administration Pack, Watchman Flx |
| United Therapeutics Corporation | $46.50 | 2019 | |
| Novo Nordisk INC | $31.95 | 2021-2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $29.42 | 2023 | Optimizer |
| Glaxosmithkline, LLC. | $24.52 | 2025 | Shingrix |
| Cvrx, INC. | $21.53 | 2021 | |
| Scpharmaceuticals INC. | $18.69 | 2024 | |
| Heartflow, INC. | $18.52 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.